logo
logo
SYK stock ticker logo

Stryker Corporation

NYSE•SYK
CEO: Mr. Kevin A. Lobo
セクター: Healthcare
業種: Medical - Devices
上場日: 1980-03-17
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
連絡先情報
1941 Stryker Way, Portage, MI, 49002, United States
269-385-2600
www.stryker.com
時価総額
$146.14B
PER (TTM)
45.0
36.1
配当利回り
0.9%
52週高値
$404.87
52週安値
$329.16
52週レンジ
70%
順位25Top 11.9%
5.6
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 5.6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$7.17B+11.42%
直近4四半期の推移

EPS

$2.21+54.55%
直近4四半期の推移

フリーCF

$1.88B+12.61%
直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Strong Net Sales Growth Reported net sales reached $25.12B, growing 11.2% compared to 2024; constant currency growth was 10.7%.
Earnings Per Share Rises Diluted EPS was $8.40, reflecting 8.2% growth; Adjusted diluted EPS grew 11.8% to $13.63.
Segment Performance Divergence MedSurg/Neurotechnology sales grew 15.7% reported, while Orthopaedics sales increased 4.3% reported in 2025.
Aggressive Capital Deployment Invested $4.96B in acquisitions, including Inari; paid $1.28B in dividends during the fiscal year.

リスク要因

Supply Chain Volatility Risks Reliance on sole-source suppliers for materials risks product shortages and increased operating costs due to inflation or tariffs.
Regulatory Burden Increases Extensive FDA and EU MDR regulations require compliance costs and could lead to sanctions, recalls, or sales restrictions.
Intellectual Property Litigation Ongoing IP infringement claims are expensive to defend and could prevent selling key products or result in damage payments.
Cybersecurity Threat Landscape Extensive reliance on IT systems faces evolving, sophisticated cyber threats, risking data integrity and operational continuity.

見通し

Mako Robotics Expansion Continued global Mako SmartRobotics footprint expansion; Mako 4 platform launched for Total Hip Advanced Primary/Revision procedures.
New Product Launches Launched OptaBlate BVN for vertebrogenic pain; Mako Shoulder commercial launch planned for Q1 2026.
Capital Structure Management Refinanced debt facilities in February 2025, increasing revolving credit capacity to $3.00B maturing in 2030.
Managing Tax Uncertainty Evaluating impact of global tax reform, including OECD Pillar 2 framework, on future effective tax rate calculations.

同業比較

売上高 (TTM)

CVS stock ticker logoCVS
$402.07B
+7.8%
MCK stock ticker logoMCK
$397.96B
+15.5%
HCA stock ticker logoHCA
$75.60B
+7.1%

粗利益率 (最新四半期)

GILD stock ticker logoGILD
86.8%
+0.7pp
VRTX stock ticker logoVRTX
85.6%
+0.7pp
AMGN stock ticker logoAMGN
81.9%
+16.1pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
AMGN$204.45B26.596.7%60.3%
GILD$184.00B21.641.0%41.7%
ISRG$177.98B62.316.4%1.5%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
6.9%
安定成長
4四半期純利益CAGR
9.1%
収益性の着実な向上
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年4月29日
|
EPS:-
|
売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書
直近12ヶ月
データなし